Cargando…
Dasatinib in the Management of Pediatric Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Acute leukemia is the most common cancer in childhood; in particular, acute lymphoblastic leukemia (ALL) represents roughly up to 80% of all cases of acute leukemias in children. Survival of children with ALL has dramatically improved over the last few decades, and is now over 90% (versus 40% of adu...
Autores principales: | Cerchione, Claudio, Locatelli, Franco, Martinelli, Giovanni |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8027101/ https://www.ncbi.nlm.nih.gov/pubmed/33842339 http://dx.doi.org/10.3389/fonc.2021.632231 |
Ejemplares similares
-
Current Concepts in Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
por: Bernt, Kathrin M., et al.
Publicado: (2014) -
Dasatinib-based 2-step induction for adults with Philadelphia chromosome–positive acute lymphoblastic leukemia
por: Sugiura, Isamu, et al.
Publicado: (2022) -
Cost-effectiveness analysis of dasatinib versus imatinib in pediatric philadelphia chromosome-positive acute lymphoblastic leukemia patients in China
por: Cao, Wang, et al.
Publicado: (2022) -
A Case of Dasatinib-Induced Nephrotic Syndrome in a Child with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
por: Lim, Young Tae, et al.
Publicado: (2016) -
Philadelphia chromosome-positive acute lymphoblastic leukemia in childhood
por: Koo, Hong Hoe
Publicado: (2011)